Silberstein S D
Jefferson Headache Center, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.
Neurology. 2000;55(9 Suppl 2):S25-8.
Because of the recurrent nature of migraine, a major concern with pharmacologic therapy is whether it will remain effective, safe, and tolerable over the long term. The development of sumatriptan offered an improvement in migraine therapy, although concerns remain about chest symptoms associated with this class of drugs. In early clinical trials, rizatriptan was shown to have good bioavailability and favorable effects on quality of life. Long-term extension trials ran for up to 12 months and compared rizatriptan with "usual care" (i.e., medications used for acute therapy). These studies showed that the 10-mg rizatriptan dose was consistently superior to usual care with regard to pain relief and complete pain relief (pain-free). Side effects were generally mild and transient in all treatment groups. Nausea, dizziness, and somnolence were the most commonly reported adverse effects.
由于偏头痛具有复发性，药物治疗的一个主要问题是长期来看它是否仍能保持有效、安全且耐受。舒马曲坦的出现改善了偏头痛治疗，尽管对于这类药物相关的胸部症状仍存在担忧。在早期临床试验中，利扎曲坦显示出良好的生物利用度以及对生活质量的有利影响。长期扩展试验持续了长达12个月，并将利扎曲坦与“常规治疗”（即用于急性治疗的药物）进行比较。这些研究表明，在缓解疼痛和完全缓解疼痛（无痛）方面，10毫克利扎曲坦剂量始终优于常规治疗。所有治疗组的副作用一般都较轻且短暂。恶心、头晕和嗜睡是最常报告的不良反应。
